The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers
Open accessAbstract
Hsp90 is an ATP dependent molecular chaperone protein which integrates multiple oncogenic pathways. As such, Hsp90 inhibition is a promising anti-cancer strategy. Several inhibitors that act on Hsp90 by binding to its N-terminal ATP pocket have entered clinical evaluation. Robust pre-clinical data suggested anti-tumor activity in multiple cancer types. Clinically, encouraging results have been demonstrated in melanoma, acute myeloid leukemia, castrate refractory prostate cancer, non-small cell lung carcinoma and multiple myeloma. In breast cancer, proof-of-concept was demonstrated by first generation Hsp90 inhibitors in combination with trastuzumab mainly in human epidermal growth factor receptor 2 (HER2) + metastatic breast cancer. There are a multitude of second generation Hsp90 inhibitors currently under investigation. To date, however, there is no FDA approved Hsp90 inhibitor nor standardized assay to ascertain Hsp90 inhibition. This review summarizes the current status of both first and second generation Hsp90 inhibitors based on their chemical classification and stage of clinical development. It also discusses the pharmacodynamic assays currently implemented in clinic as well as other novel strategies aimed at enhancing the effectiveness of Hsp90 inhibitors. Ultimately, these efforts will aid in maximizing the full potential of this class of agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the dynamic HSP90 complex in cancer
Trepel, J., Mollapour, M., Giaccone, G., & Neckers, L. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2887 · Cited by 1,514
Whitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E., & Neckers, L. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8324 · Cited by 1,444
A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
Kamal, A., Thao, L., Sensintaffar, J., Zhang, L., Boehm, M. F., Fritz, L. C., & Burrows, F. J. (2003) · Nature · doi:10.1038/nature01913 · Cited by 1,387
Prodromou, C., Roe, S. M., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1997) · Cell · doi:10.1016/s0092-8674(00)80314-1 · Cited by 1,265
Grenert, J. P., Sullivan, W. P., Fadden, P., Haystead, T. A. J., Clark, J., Mimnaugh, E., Krutzsch, H., Ochel, H.-J., Schulte, T. W., Sausville, E., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.38.23843 · Cited by 569
WORKMAN, P., BURROWS, F., NECKERS, L., & ROSEN, N. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1391.012 · Cited by 521
Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent
Supko, J. G., Hickman, R. L., Grever, M. R., & Malspeis, L. (1995) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00689048 · Cited by 510
Banerji, U., O'Donnell, A., Scurr, M., Pacey, S., Stapleton, S., Asad, Y., Simmons, L., Maloney, A., Raynaud, F., Campbell, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.612 · Cited by 488
Eccles, S. A., Massey, A., Raynaud, F. I., Sharp, S. Y., Box, G., Valenti, M., Patterson, L., de Haven Brandon, A., Gowan, S., Boxall, F., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5256 · Cited by 479
Schulte, T. W., & Neckers, L. M. (1998) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050817 · Cited by 478
GELDANAMYCIN, A NEW ANTIBIOTIC
DEBOER, C., MEULMAN, P. A., WNUK, R. J., & PETERSON, D. H. (1970) · The Journal of Antibiotics · doi:10.7164/antibiotics.23.442 · Cited by 466
The Hsp90 molecular chaperone: an open and shut case for treatment
Pearl, L. H., Prodromou, C., & Workman, P. (2008) · Biochemical Journal · doi:10.1042/bj20071640 · Cited by 447
Modi, S., Stopeck, A., Linden, H., Solit, D., Chandarlapaty, S., Rosen, N., D'Andrea, G., Dickler, M., Moynahan, M. E., Sugarman, S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0072 · Cited by 424
Self-citationPhase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients With Advanced Cancer
Goetz, M. P., Toft, D., Reid, J., Ames, M., Stensgard, B., Safgren, S., Adjei, A. A., Sloan, J., Atherton, P., Vasile, V., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.119 · Cited by 336
Modi, S., Stopeck, A. T., Gordon, M. S., Mendelson, D., Solit, D. B., Bagatell, R., Ma, W., Wheler, J., Rosen, N., Norton, L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.7960 · Cited by 335
Self-citationSequist, L. V., Gettinger, S., Senzer, N. N., Martins, R. G., Jänne, P. A., Lilenbaum, R., Gray, J. E., Iafrate, A. J., Katayama, R., Hafeez, N., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.8338 · Cited by 330
Caldas-Lopes, E., Cerchietti, L., Ahn, J. H., Clement, C. C., Robles, A. I., Rodina, A., Moulick, K., Taldone, T., Gozman, A., Guo, Y., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903392106 · Cited by 315
Self-citationChiosis, G., Timaul, M. N., Lucas, B., Munster, P. N., Zheng, F. F., Sepp-Lorenzino, L., & Rosen, N. (2001) · Chemistry & Biology · doi:10.1016/s1074-5521(01)00015-1 · Cited by 288
Self-citationSolit, D. B., Basso, A. D., Olshen, A. B., Scher, H. I., & Rosen, N. X. (2003) · PubMed · Cited by 277
A New Antifungal Substance of Fungal Origin
DELMOTTE, P., & DELMOTTE-PLAQUEE, J. (1953) · Nature · doi:10.1038/171344a0 · Cited by 271
Bagatell, R., Paine-Murrieta, G. D., Taylor, C. W., Pulcini, E. J., Akinaga, S., Benjamin, I. J., & Whitesell, L. J. (2000) · PubMed · Cited by 269
Woodhead, A. J., Angove, H., Carr, M. G., Chessari, G., Congreve, M., Coyle, J. E., Cosme, J., Graham, B., Day, P. J., Downham, R., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100060b · Cited by 264
Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90
Moulick, K., Ahn, J. H., Zong, H., Rodina, A., Cerchietti, L., Gomes DaGama, E. M., Caldas-Lopes, E., Beebe, K., Perna, F., Hatzi, K., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.670 · Cited by 261
Self-citationDevelopment and application of Hsp90 inhibitors
Solit, D. B., & Chiosis, G. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.10.007 · Cited by 251
Self-citationHsp90 and co‐chaperones twist the functions of diverse client proteins
Zuehlke, A., & Johnson, J. L. (2010) · Biopolymers · doi:10.1002/bip.21292 · Cited by 251
Grem, J. L., Morrison, G., Guo, X.-D., Agnew, E., Takimoto, C. H., Thomas, R., Szabo, E., Grochow, L., Grollman, F., Hamilton, J. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.085 · Cited by 242
Sydor, J. R., Normant, E., Pien, C. S., Porter, J. R., Ge, J., Grenier, L., Pak, R. H., Ali, J. A., Dembski, M. S., Hudak, J., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608372103 · Cited by 231
Cheung, K.-M. J., Matthews, T. P., James, K., Rowlands, M. G., Boxall, K. J., Sharp, S. Y., Maloney, A., Roe, S. M., Prodromou, C., Pearl, L. H., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.05.046 · Cited by 219
Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer
Solit, D. B., Ivy, S. P., Kopil, C., Sikorski, R., Morris, M. J., Slovin, S. F., Kelly, W. K., DeLaCruz, A., Curley, T., Heller, G., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1863 · Cited by 211
Ramanathan, R. K., Trump, D. L., Eiseman, J. L., Belani, C. P., Agarwala, S. S., Zuhowski, E. G., Lan, J., Potter, D. M., Ivy, S. P., Ramalingam, S., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2322 · Cited by 194
Pacey, S., Wilson, R. H., Walton, M., Eatock, M. M., Hardcastle, A., Zetterlund, A., Arkenau, H.-T., Moreno-Farre, J., Banerji, U., Roels, B., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1927 · Cited by 190
Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma
Solit, D. B., Osman, I., Polsky, D., Panageas, K. S., Daud, A., Goydos, J. S., Teitcher, J., Wolchok, J. D., Germino, F. J., Krown, S. E., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1002 · Cited by 190
Heath, E. I., Hillman, D. W., Vaishampayan, U., Sheng, S., Sarkar, F., Harper, F., Gaskins, M., Pitot, H. C., Tan, W., Ivy, S. P., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0221 · Cited by 186
Chandarlapaty, S., Sawai, A., Ye, Q., Scott, A., Silinski, M., Huang, K., Fadden, P., Partdrige, J., Hall, S., Steed, P., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1667 · Cited by 186
Murray, C. W., Carr, M. G., Callaghan, O., Chessari, G., Congreve, M., Cowan, S., Coyle, J. E., Downham, R., Figueroa, E., Frederickson, M., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100059d · Cited by 184
HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans
Marubayashi, S., Koppikar, P., Taldone, T., Abdel-Wahab, O., West, N., Bhagwat, N., Caldas-Lopes, E., Ross, K. N., Gönen, M., Gozman, A., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42442 · Cited by 184
Self-citationBenzoquinonoid ansamycins possess selective tumoricidal activity unrelated to src kinase inhibition.
Whitesell, L. J., Shifrin, S. D., Schwab, G., & Neckers, L. M. (1992) · PubMed · Cited by 176
Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET.
Smith-Jones, P. M., Solit, D. B., Afroze, F., Rosen, N. X., & Larson, S. M. (2006) · PubMed · Cited by 173
Münster, P. N., Basso, A., Solit, D., Norton, L., & Rosen, N. (2001) · PubMed · Cited by 173
Lundgren, K., Zhang, H., Brekken, J., Huser, N., Powell, R. E., Timple, N., Busch, D. J., Neely, L., Sensintaffar, J. L., Yang, Y.-C., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0758 · Cited by 173
Targeting Wide-Range Oncogenic Transformation via PU24FCl, a Specific Inhibitor of Tumor Hsp90
Vilenchik, M., Solit, D., Basso, A., Huezo, H., Lucas, B., He, H., Rosen, N., Spampinato, C., Modrich, P., & Chiosis, G. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.04.008 · Cited by 171
Self-citationHsp90: A Novel Target for Cancer Therapy
Solit, D., & Rosen, N. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606777812068 · Cited by 170
Hsp90 Inhibition Depletes Chk1 and Sensitizes Tumor Cells to Replication Stress
Arlander, S. J. H., Eapen, A. K., Vroman, B. T., McDonald, R. J., Toft, D. O., & Karnitz, L. M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m309054200 · Cited by 169
ATPases as drug targets: learning from their structure
Chène, P. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd894 · Cited by 163
Discovery and development of heat shock protein 90 inhibitors
Taldone, T., Sun, W., & Chiosis, G. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.10.087 · Cited by 162
Self-citationCerchietti, L. C., Lopes, E. C., Yang, S. N., Hatzi, K., Bunting, K. L., Tsikitas, L. A., Mallik, A., Robles, A. I., Walling, J., Varticovski, L., et al. (2009) · Nature Medicine · doi:10.1038/nm.2059 · Cited by 161
Self-citationLancet, J. E., Gojo, I., Burton, M., Quinn, M. F., Tighe, S., Kersey, K., Zhong, Z., Albitar, M. X., Bhalla, K. N., Hannah, A. L., et al. (2010) · Leukemia · doi:10.1038/leu.2009.292 · Cited by 156
Hollingshead, M. G., Alley, M. C., Burger, A. M., Borgel, S. D., Pacula-Cox, C. M., Fiebig, H., & Sausville, E. A. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0939-2 · Cited by 153
Ronnen, E. A., Kondagunta, G. V., Ishill, N. M., Sweeney, S. M., DeLuca, J., Schwartz, L. H., Bacik, J., & Motzer, R. J. (2006) · Investigational New Drugs · doi:10.1007/s10637-006-9208-z · Cited by 147
Rajan, A., Kelly, R. J., Trepel, J. B., Kim, Y. S., Alarcon, S. V., Kummar, S., Gutierrez, M. E., Crandon, S. K., Zein, W. M., Jain, L., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0821 · Cited by 146
Holland, J. P., Caldas-Lopes, E., Divilov, V., Longo, V. A., Taldone, T., Zatorska, D., Chiosis, G., & Lewis, J. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008859 · Cited by 142
Self-citationKasibhatla, S. R., Hong, K., Biamonte, M. A., Busch, D. J., Karjian, P. L., Sensintaffar, J., Kamal, A., Lough, R. E., Brekken, J., Lundgren, K., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm050752+ · Cited by 126
Chandarlapaty, S., Scaltriti, M., Angelini, P. D., Ye, Q., Guzmán, M., Hudis, C. A., Norton, L., Solit, D. B., Arribas, J., Baselga, J. M., et al. (2009) · Oncogene · doi:10.1038/onc.2009.337 · Cited by 126
Kummar, S., Gutierrez, M. E., Gardner, E. R., Chen, X., Figg, W. D., Zajac‐Kaye, M., Chen, M., Steinberg, S. M., Muir, C. A., Yancey, M. A., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.10.026 · Cited by 122
Richardson, P. G. G., Chanan-Khan, A. A., Lonial, S., Krishnan, A. Y., Carroll, M. P., Alsina, M., Albitar, M. X., Berman, D., MESSINA, M. E., & Anderson, K. C. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08664.x · Cited by 118
Nowakowski, G. S., McCollum, A. K., Ames, M. M., Mandrekar, S. J., Reid, J. M., Adjei, A. A., Toft, D. O., Safgren, S. L., & Erlichman, C. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1015 · Cited by 114
Nagengast, W. B., de Korte, M. A., Munnink, T. H. O., Timmer‐Bosscha, H., den Dunnen, W. F. A., Hollema, H., de Jong, J. R., Jensen, M. R., Quadt, C., García-Echeverría, C., et al. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.071043 · Cited by 113
The Role of Checkpoint Kinase 1 in Sensitivity to Topoisomerase I Poisons
Flatten, K. S., Dai, N. T., Vroman, B. T., Loegering, D. A., Erlichman, C., Karnitz, L. M., & Kaufmann, S. H. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411890200 · Cited by 104
Recent Advances in Hsp90 Inhibitors as Antitumor Agents
Messaoudi, S., Peyrat, J., Brion, J., & Alami, M. (2008) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152008785914824 · Cited by 103
Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment
Patel, H., Modi, S., Chiosis, G., & Taldone, T. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.563296 · Cited by 103
Self-citationNakashima, T., Ishii, T., Tagaya, H., Seike, T., Nakagawa, H., Kanda, Y., Akinaga, S., Soga, S., & Shiotsu, Y. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3112 · Cited by 97
ATPase inhibitors of heat-shock protein 90, second season
Janin, Y. L. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.03.002 · Cited by 95
Bagatell, R., Gore, L., Egorin, M. J., Ho, R. H., Heller, G., Boucher, N., Zuhowski, E. G., Whitlock, J. A., Hunger, S. P., Narendran, A., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1892 · Cited by 95
Fadden, P., Huang, K. H., Veal, J. M., Steed, P. M., Barabasz, A. F., Foley, B. E., Hu, M., Partridge, J. M., Rice, J. W., Scott, A., et al. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.04.015 · Cited by 93
Ramanathan, R. K., Egorin, M. J., Erlichman, C., Remick, S. C., Ramalingam, S. S., Naret, C., Holleran, J. L., TenEyck, C. J., Ivy, S. P., & Belani, C. P. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0415 · Cited by 89
Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose‐escalation study
Richardson, P. G. G., Chanan-Khan, A. A., Alsina, M., Albitar, M. X., Berman, D., MESSINA, M. E., Mitsiades, C. S., & Anderson, K. C. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08265.x · Cited by 85
Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma
Richardson, P. G. G., Badros, A. Z., Jagannath, S., Tarantolo, S., Wolf, J. L., Albitar, M. X., Berman, D., MESSINA, M. E., & Anderson, K. C. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08264.x · Cited by 84
Mechanistic Evaluation of the Novel HSP90 Inhibitor NVP-AUY922 in Adult and Pediatric Glioblastoma
Gaspar, N., Sharp, S. Y., Eccles, S. A., Gowan, S. M., Popov, S., Jones, C., Pearson, A. D. J., Vassal, G., & Workman, P. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0683 · Cited by 82
Chaperoning Oncogenes: Hsp90 as a Target of Geldanamycin
Neckers, L. (2005) · Handbook of experimental pharmacology · doi:10.1007/3-540-29717-0_11 · Cited by 81
Weigel, B. J., Blaney, S. M., Reid, J. M., Safgren, S. L., Bagatell, R., Kersey, J., Neglia, J. P., Ivy, S. P., Ingle, A. M., Whitesell, L. J., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2270 · Cited by 80
Nguyen, D. M., Lorang, D., Chen, G. A., Stewart, J. H., Tabibi, E., & Schrump, D. S. (2001) · The Annals of Thoracic Surgery · doi:10.1016/s0003-4975(01)02787-4 · Cited by 78
Purine-Scaffold Hsp90 Inhibitors
Taldone, T., & Chiosis, G. (2009) · Current Topics in Medicinal Chemistry · doi:10.2174/156802609789895737 · Cited by 74
Self-citationBIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy
Yin, X., Zhang, H., Lundgren, K., Wilson, L. D., Burrows, F. J., & Shores, C. G. (2009) · International Journal of Cancer · doi:10.1002/ijc.24815 · Cited by 70
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Hermiston, T. W., & Kirn, D. H. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.01.001 · Cited by 65
Vaishampayan, U. N., Burger, A. M., Sausville, E. A., Heilbrun, L. K., Li, J., Horiba, M. N., Egorin, M. J., Ivy, P. S., Pacey, S., & LoRusso, P. M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0503 · Cited by 64
Wong, K., Koczywas, M., Goldman, J. W., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.7500 · Cited by 62
Identification of new biomarkers for clinical trials of Hsp90 inhibitors
Zhang, H., Chung, D., Yang, Y., Neely, L., Tsurumoto, S., Fan, J., Zhang, L., Biamonte, M. A., Brekken, J., Lundgren, K., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0537 · Cited by 61
Ramalingam, S. S., Egorin, M. J., Ramanathan, R. K., Remick, S. C., Sikorski, R. P., Lagattuta, T. F., Chatta, G. S., Friedland, D., Stoller, R. G., Potter, D. M., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5088 · Cited by 61
Bao, R., Lai, C.-J., Wang, D.-G., Qu, H., Yin, L., Zifcak, B. M., Tao, X., Wang, J., Atoyan, R., Samson, M., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0538 · Cited by 60
Tse, A. N., Klimstra, D. S., Gönen, M., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1006 · Cited by 59
Cisplatin abrogates the geldanamycin-induced heat shock response
McCollum, A. K., Lukasiewicz, K. B., TenEyck, C. J., Lingle, W. L., Toft, D. O., & Erlichman, C. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0157 · Cited by 56
Samuel, T. A., Sessa, C., Britten, C. D., Milligan, K., Mita, M. M., Banerji, U., Pluard, T., Stiegler, P., Quadt, C., & Shapiro, G. I. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.2528 · Cited by 43
Demetri, G. D., Heinrich, M. C., Chmielowski, B., Morgan, J. A., George, S., Bradley, R., Blackman, R. K., Teofilovici, F., Fletcher, J., Tap, W. D., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.10011 · Cited by 41
Hubbard, J. M., Erlichman, C., Toft, D. O., Qin, R., Stensgard, B. A., Felten, S. J., Eyck, C. T., Batzel, G. N., Ivy, S. P., & Haluska, P. (2010) · Investigational New Drugs · doi:10.1007/s10637-009-9381-y · Cited by 38
Bryson, J. C., Infante, J. R., Ramanathan, R. K., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.14613 · Cited by 20
Cleary, J. M., Heath, E. I., Kwak, E. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3083 · Cited by 20
Goldman, J. W., Raju, R. N., Gordon, G. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.2529 · Cited by 19
Cho, D. C., Heath, E. I., Cleary, J. M., Kwak, E. L., Gandhi, L., Lawrence, D. P., Zack, C. J., Teofilovici, F., Bradley, R., Karol, M. D., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3051 · Cited by 18
Eiseman, J. L., Guo, J., Ramanathan, R. K., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2286 · Cited by 15
Modi, S., Ismail-Khan, R., Münster, P. N., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.sabcs10-p3-14-02 · Cited by 14
Self-citationBiogen Idec restructures, sharpens neurology focus
Mitchell, P. C. (2011) · Nature Biotechnology · doi:10.1038/nbt0111-7 · Cited by 14
(1972) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/49.4.1216 · Cited by 13
Lancet, J. E., Smith, B. D., Bradley, R. H., Komrokji, R. S., Teofilovici, F., & Rizzieri, D. A. (2010) · Blood · doi:10.1182/blood.v116.21.3294.3294 · Cited by 9
Padmanabhan, S., Kelly, K. R., Heaney, M. L., Hodges, S., Chanel, S. M., Frattini, M. G., Swords, R. T., Bradley, R. H., Teofilovici, F., & DeAngelo, D. J. (2010) · Blood · doi:10.1182/blood.v116.21.2898.2898 · Cited by 7
Cited by
Targeting the unfolded protein response in disease
Hetz, C., Chevet, E., & Harding, H. P. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3976 · Cited by 910
Small‐Molecule PROTACS: New Approaches to Protein Degradation
Toure, M., & Crews, C. M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201507978 · Cited by 674
Targeting Heat Shock Proteins in Cancer: A Promising Therapeutic Approach
Chatterjee, S., & Burns, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091978 · Cited by 501
The Hsp70/Hsp90 Chaperone Machinery in Neurodegenerative Diseases
Lackie, R. E., Maciejewski, A., Ostapchenko, V. G., Marques-Lopes, J., Choy, W.-Y., Duennwald, M. L., Prado, V. F., & Prado, M. A. M. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00254 · Cited by 374
Inhibition of HSP90 molecular chaperones: moving into the clinic
Garcia-Carbonero, R., Carnero, A., & Paz-Ares, L. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70169-4 · Cited by 351
Metadata
- Authors
- Jhaveri, K., Taldone, T., Modi, S., & Chiosis, G.
- Venue
- Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
- Publisher
- Elsevier BV
- Published
- 2012-03
- Volume
- 1823
- Issue
- 3
- Pages
- 742-755
- ISSN
- 0167-4889 (ISSN-L)
- OpenAlex
- W1988675578
- Cited by
- 456
- References
- 94
- FWCI
- 14.34
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.